What You Should Know:
- Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047.
- The company has also been awarded a $2.3 million Phase II Small Business Innovation Research (SBIR) Grant
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Zephyr AI Secures $111M to Democratize Precision Medicine with Explainable AI
What You Should Know:
- Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group.
- The company plans to use this round of funding to refine its technology to fortify its extensive collection of training and validation datasets, crucial for robust AI models, deliver results even faster, and expand its scientific and commercial
Read More
Sano Genetics Secures $11.4M to Turbocharge Precision Medicine Research
What You Should Know:
- Sano Genetics, a software company that is revolutionizing precision medicine research, has secured $11.4M in new funding.
- This latest investment, led by Plural with participation from existing investors MMC Ventures, Episode 1, and Seedcamp, brings the company's total funding to $22M.
Revolutionizing Precision Medicine Research
Founded by a trio of visionary minds - Patrick Short (CEO), Charlotte Guzzo (COO), and William Jones (CTO) - Sano Genetics is
Read More
Drug-Gene Interactions: Minimizing Risk with Pharmacogenomics
Every individual responds differently to medications, and their reactions can vary greatly. While a specific drug may be effective for one person with no adverse effects, another individual may experience a negative reaction to the same medication. Pharmacogenomic (PGx) testing enables the identification of patients who are prone to adverse drug reactions, individuals who are more likely to benefit from specific medications and those who may require adjusted dosages. As adverse drug reactions
Read More
Prenosis Awarded $4.8M in NIH Grants to Enable Precision Medicine for Sepsis
What You Should Know:
Prenosis, Inc., a Chicago, IL-based AI company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH). The grants will study the use of Prenosis's Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial
Read More
Expectations For The Connected Care Business In The Years Ahead
Though we seldom see their use in our modern world and, even then, only in fiction, there was a time when it was common for people to actually use things like crystal balls and divining rods to try to uncover unknown yet valuable information. As unbelievable as it may seem, soothsayers peered into crystal balls aiming to help seekers look into the future for guidance, while prospectors would rely earnestly on divining rods as they attempted to locate underground riches of water or oil.
While
Read More
Phenomix Sciences Launches Saliva Test to Predict Obesity Phenotype
What You Should Know:
- Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces today the launch of its first therapy selection test, the My Phenome Hungry Gut test.
- This is a first-of-its-kind obesity test and will determine if a patient’s phenotype is Hungry Gut (Satiety) or feeling hungry shortly after eating a meal. If a patient is Hungry Gut phenotyped, providers are able to more precisely and
Read More
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More
Accenture: Data Collaboratives Hold Great Promise for Accelerated Healthcare Progress and Precision Medicine
What You Should Know:
- Accenture published Fast-Forwarding Healthcare through Data Collaboratives Report to discover how best health ecosystem players access data to fast-forward healthcare.
- Data generated by technical and scientific advances, like connected health devices, consumer health and medical-grade digital apps, individual multi-omics profiling data and the move to cloud storage, holds great promise for accelerated healthcare progress and precision medicine, and data
Read More
PathGroup Expands Operations with Proscia Concentriq Dx
What You Should Know:
- PathGroup, one of the largest providers of anatomic, clinical, digital, and molecular pathology services in the United States, is expanding its operations with Proscia's software platform (Concentriq® Dx) to further enhance the delivery of faster, higher quality results for millions of patients, helping to better inform treatment decisions.
- PathGroup currently supports more than 15,000 referring physicians and over 200 hospital
Read More
